Skip to content
806-Converting Tregs into Type 1 Tumor Effectors episode artwork

Apr 17, 2026 24 min

806-Converting Tregs into Type 1 Tumor Effectors

from Paper Talk

This research reveals that agonistic anti-CD40 antibody therapy effectively eliminates immunosuppressive regulatory T (Treg) cells by forcing them to undergo a functional transformation. Within the tumor microenvironment, this treatment triggers a conversion process where Treg cells lose their Foxp3 expression and evolve into activated "ExTreg" cells. These reprogrammed cells adopt a Th1-like phenotype, characterized by the production of IFN-γ and increased antigen reactivity. This plasticity is driven by CD40-activated dendritic cells and the IL-12/IFN-γ cytokine axis, which also causes the cells to relocate to the tumor periphery. Ultimately, the study demonstrates that αCD40 immunotherapy can flip a pro-tumor suppressive state into a potent, localized anti-tumor immune response. References: Maltez V I, Arora C, Gribbin K P, et al. Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment[J]. Immunity, 2026. 前往小宇宙评论区与主播互动

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

806-Converting Tregs into Type 1 Tumor Effectors

0:00 24:11

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Paper Talk?

This episode is 24 minutes long.

When was this Paper Talk episode published?

This episode was published on April 17, 2026.

Can I download this Paper Talk episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.